Dashboard
Manage Tickers

BFRI Biofrontera Inc.

Nasdaq biofrontera.us.com


$ 0.98 $ 0.02 (2.55 %)    

Wednesday, 15-Oct-2025 15:21:43 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.42 $ 4.22 (0.71 %)
DIA $ 463.02 $ 0.00 (0 %)
SPY $ 664.84 $ 2.94 (0.44 %)
TLT $ 90.75 $ -0.20 (-0.22 %)
GLD $ 387.26 $ 6.60 (1.73 %)
$ 0.9816
$ 1.00
$ 0.98 x 30
$ 1.10 x 75
$ 0.96 - $ 1.03
$ 0.54 - $ 2.22
47,489
na
10.47M
$ 3.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-15-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-13-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 04-09-2022 12-31-2021 10-K
16 11-30-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

biofrontera-completes-treatment-phase-in-phase-3-trial-of-ameluz-for-actinic-keratosis-on-body-supplemental-new-drug-application-planned-for-submission-in-q2-2026
Biofrontera Completes Treatment Phase In P...
09/16/2025 14:32:20

All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in ...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/08/2025 21:07:27

biofrontera-completes-final-patient-visit-in-phase-2b-acne-trial-top-line-results-expected-q1-2026-plans-fda-discussion-for-phase-3-in-q3
Biofrontera Completes Final Patient Visit ...
08/25/2025 12:26:48

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in ...

biofrontera-q2-eps-057-misses-042-estimate-sales-903m-beat-830m-estimate
Biofrontera Q2 EPS $(0.57) Misses $(0.42) ...
08/13/2025 21:21:22

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.42)...

Core News & Articles
Earnings Scheduled For August 13, 2025
08/13/2025 08:32:30

a-look-at-biofronteras-upcoming-earnings-report
A Look at Biofrontera's Upcoming Earnings ...
08/12/2025 17:02:37

biofrontera-inc-acquires-all-us-rights-to-ameluz-and-rhodoled-from-former-parent-co-biofrontera-ag-coupled-with-11m-financing-led-bt-existing-investors-under-new-agreement-effective-royalty-rate-paid-by-co-will-be-reduced-to-12-of-net-sales
Biofrontera Inc. Acquires All US Rights To...
06/30/2025 12:02:35

Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Applicati...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
06/16/2025 12:08:38

biofrontera-confirms-talks-with-biofrontera-ag-on-potential-merger-or-deal-restructuring-to-lower-us-product-costs
Biofrontera Confirms Talks With Biofronter...
06/11/2025 19:02:19

Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic th...

biofronteras-propylene-glycol-free-ameluz-formulation-receives-fda-orange-book-listing-following-april-2025-patent-approval-extending-protection-through-2043
Biofrontera's Propylene Glycol-Free Ameluz...
06/03/2025 18:34:29

Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through ...

benchmark-maintains-buy-on-biofrontera-lowers-price-target-to-275
Benchmark Maintains Buy on Biofrontera, Lo...
05/19/2025 14:40:12

Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $7 to $2.75.

why-quantum-computing-shares-are-trading-higher-by-around-12-here-are-20-stocks-moving-premarket
Why Quantum Computing Shares Are Trading H...
05/16/2025 08:56:24

biofrontera-q1-eps-047-misses-021-estimate-sales-859m-miss-1055m-estimate
Biofrontera Q1 EPS $(0.47) Misses $(0.21) ...
05/15/2025 20:57:49

biofrontera-receives-patent-approval-for-updated-formulation-of-ameluz-nanoemulsion-gel-without-propylene-glycol-through-to-december-2043
Biofrontera Receives Patent Approval For U...
05/15/2025 16:20:37

Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends patent protection through to Dec...

Core News & Articles
Earnings Scheduled For May 15, 2025
05/15/2025 08:32:23

an-overview-of-biofronteras-earnings
An Overview of Biofrontera's Earnings
05/14/2025 19:04:53

biofrontera-q4-2024-gaap-eps-019-beats-024-estimate-sales-1256m-beat-1150m-estimate
Biofrontera Q4 2024 GAAP EPS $(0.19) Beats...
03/21/2025 12:01:49

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.24) b...

biofrontera-fy-2024-gaap-eps-322-may-not-be-comparable-to-085-estimate-sales-3732m-miss-4706m-estimate
Biofrontera FY 2024 GAAP EPS $(3.22) May N...
03/21/2025 11:25:46

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(3.22) per share which missed the analyst consensus estimate of $(0.85)...

earnings-scheduled-for-march-21-2025
Earnings Scheduled For March 21, 2025
03/21/2025 08:32:07

biofrontera-completes-patient-enrollment-of-phase-3-study-of-ameluz-topical-gel-10-for-actinic-keratoses-on-extremities
Biofrontera Completes Patient Enrollment O...
03/18/2025 13:31:26

First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT tre...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION